Starlet

Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC

Retrieved on: 
Monday, July 31, 2023

Seegene showcased its "unique syndromic quantitative PCR assays and automated PCR solution 'STARlet AIOS™ (All-in-One System).'"

Key Points: 
  • Seegene showcased its "unique syndromic quantitative PCR assays and automated PCR solution 'STARlet AIOS™ (All-in-One System).'"
  • Meanwhile, an in-depth discussion was conducted in the symposium sessions on the usefulness of PCR testing in diagnosing gastrointestinal diseases.
  • Celebrating its 75th year, AACC is the world's largest gathering for the clinical laboratory and diagnostics industry.
  • Seegene has taken part since 2007 to broadcast its proprietary molecular diagnostic technology worldwide while establishing cooperation with partners from multiple countries.

GWM Holds a Global Car Festival to Upgrade Customer Experience

Retrieved on: 
Tuesday, June 6, 2023

BAODING, China, June 6, 2023 /PRNewswire/ -- Recently, GWM has begun a global Car Festival in overseas markets to make full use of its dominant position in intelligent new energy vehicles (NEVs) and upgrade customer experience.

Key Points: 
  • BAODING, China, June 6, 2023 /PRNewswire/ -- Recently, GWM has begun a global Car Festival in overseas markets to make full use of its dominant position in intelligent new energy vehicles (NEVs) and upgrade customer experience.
  • To meet the needs of consumers in different markets for environmental protection and technological configuration, GWM has successively launched HAVAL H6 HEV and HAVAL H6 PHEV.
  • GWM POER is a premium intelligent pickup produced by GWM, designed to integrate superior off-road performance, exceptional loading capacity and cutting-edge intelligent technology.
  • In the future, GWM will concentrate on the global brand action plan of "ONE GWM", leveraging the launch of intelligent NEVs to enhance consumer experience continuously, increase popularity, and provide high-quality, personalized mobility experiences for consumers worldwide.

GWM Holds a Global Car Festival to Upgrade Customer Experience

Retrieved on: 
Tuesday, June 6, 2023

BAODING, China, June 6, 2023 /PRNewswire/ -- Recently, GWM has begun a global Car Festival in overseas markets to make full use of its dominant position in intelligent new energy vehicles (NEVs) and upgrade customer experience.

Key Points: 
  • BAODING, China, June 6, 2023 /PRNewswire/ -- Recently, GWM has begun a global Car Festival in overseas markets to make full use of its dominant position in intelligent new energy vehicles (NEVs) and upgrade customer experience.
  • To meet the needs of consumers in different markets for environmental protection and technological configuration, GWM has successively launched HAVAL H6 HEV and HAVAL H6 PHEV.
  • GWM POER is a premium intelligent pickup produced by GWM, designed to integrate superior off-road performance, exceptional loading capacity and cutting-edge intelligent technology.
  • In the future, GWM will concentrate on the global brand action plan of "ONE GWM", leveraging the launch of intelligent NEVs to enhance consumer experience continuously, increase popularity, and provide high-quality, personalized mobility experiences for consumers worldwide.

Hamilton and BioFluidica Pen Next Generation Liquid Biopsy Platform Co-Marketing Agreement

Retrieved on: 
Tuesday, September 27, 2022

SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Biofluidica, Inc., and Hamilton Company, today announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide. Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers (Microlab® STAR™ and STARlet™) to process biological samples to isolate extremely rare circulating tumor cells (CTCs), circulating Leukemic cells (CLCs), fetal cells, cfDNA, and exosomes. The Biofluidica platform, LiquidScan™, integrates seamlessly into the Hamilton pipetting robots. The high precision fluid control provided by the Hamilton automated pipetting channels is designed to avoid processing loss using the Biofluidica proprietary closed-loop pipetting interface with the Biofluidica microfluidic biomarker selection chips.

Key Points: 
  • SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Biofluidica, Inc., and Hamilton Company, today announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide.
  • Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers (Microlab STAR and STARlet) to process biological samples to isolate extremely rare circulating tumor cells (CTCs), circulating Leukemic cells (CLCs), fetal cells, cfDNA, and exosomes.
  • The Biofluidica platform, LiquidScan, integrates seamlessly into the Hamilton pipetting robots.
  • BioFluidica Inc. is a privately held biotechnology company that has developed a revolutionary liquid biopsy platform.

Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing

Retrieved on: 
Thursday, October 28, 2021

Incorporates Seegene's broad menu of molecular diagnostics for syndromic testing, for detection of SARS-CoV-2 and variants.

Key Points: 
  • Incorporates Seegene's broad menu of molecular diagnostics for syndromic testing, for detection of SARS-CoV-2 and variants.
  • "Seegene has played a critical role in the global response to the COVID-19 pandemic, in large part because of our forward-looking strategy.
  • "As we look ahead, the most pressing diagnostic need will be for cost-effective and high throughput automated systems that can remove any remaining testing bottlenecks.
  • The modular design ofSTARlet-AIOS: All-in-One Systemunites twostandalone instrumentsthe STARlet IVD and the CFX96 Dx real-time PCR Systemwitha custom-built robotic arm.

Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing

Retrieved on: 
Wednesday, October 27, 2021

Utilizes Seegene's broad menu of molecular diagnostics for syndromic testing, for detection of SARS-CoV-2 and variants.

Key Points: 
  • Utilizes Seegene's broad menu of molecular diagnostics for syndromic testing, for detection of SARS-CoV-2 and variants.
  • "Seegene has played a critical role in the global response to the COVID-19 pandemic, in large part because of our forward-looking strategy.
  • "As we look ahead, the most pressing diagnostic need will be for cost-effective and high throughput automated systems that can remove any remaining testing bottlenecks.
  • The modular design ofSTARlet-AIOS: All-in-One Systemunites twostandalone instrumentsthe STARlet IVD and the CFX96 Dx real-time PCR Systemwitha custom-built robotic arm.